Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Rouen
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Older than 18 or parental agreement in case of children.
For patient with early-onset breast cancer :
Invasive breast cancer, regardless of histological type or stage, diagnosed before 31 years.
Sporadic or familial presentation
No genomic alterations of BRCA1, BRCA2 or TP53
For patient with early-onset ovarian cancer :
Invasive ovarian cancer, regardless of histological type or stage, diagnosed before 41 years.
Sporadic or familial presentation
No genomic alterations of BRCA1, BRCA2
Patient with early-onset colorectal cancer :
Invasive colorectal cancer diagnosed before 31 years.
Sporadic or familial presentation
No genomic alteration of MSH2, MLH1 or MSH6 in case of HNPCC presentation
No genomic alteration of APC, MUTYH, SMAD4, BMPR1A, PTEN or STK11 in case of adenomatous polyposis or hamartoma presentation
Patient with pediatric cancer :
Non haematological tumour diagnosed before 16 years, with Li-Fraumeni presentation.
No genomic alteration of TP53
Patient with Multiple primary malignant tumours :
Multiple synchronous or metachronous primary malignant tumors with early-onset
No syndromic presentation
You may not be if
Any already known deleterious mutations according to the patient's phenotype
Clareo Health | Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation
